Hantavirus outbreak refocuses investors on Moderna and peers

A hantavirus outbreak aboard the research vessel MV Hondius in May coincided with renewed trading in stocks tied to pandemic preparedness, lifting several names and increasing trading volume in vaccine and biodefense companies.

Moderna shares rose from $43.69 on May 1 to $59.45 on May 11, an increase of about 36%, with volume rising during the advance. The company reported Q1 2026 revenue of $389 million, up 260% year‑over‑year, disclosed a collaboration with the U.S. Army Medical Research Institute of Infectious Diseases on a hantavirus vaccine program, and published Phase 3 data for its mRNA‑1010 influenza candidate. On daily charts the stock shows a cup‑and‑handle pattern with a cup bottom at $43.69 and a rim near $59.45; the handle is forming above the 20‑day exponential moving average at about $50.50. A daily close above $54.91 would start a handle breakout; a close above $60.96 would confirm the pattern and project a measured objective near $81.46. The pattern would be invalidated if the price falls below $43.69.

Emergent BioSolutions shares fell from $14.07 to $7.53 earlier this year, a decline of about 44%. On March 1 the company guided fiscal 2026 revenue to $720 million–$760 million. On April 30 it reported Q1 2026 revenue of $156.1 million, down 30% year‑over‑year, citing lower U.S. government orders for medical countermeasures. Daily charts show an inverse head‑and‑shoulders pattern with a left shoulder near $7.82, a head at $7.53 and a developing right shoulder around $8.33; a daily close above $10.02, near the neckline, would confirm a breakout and imply a measured target near $12.65. A break below $7.53 would invalidate the pattern.

BioNTech has formed a head‑and‑shoulders pattern since March, with a left shoulder near $100 in mid‑March, a head at $113.55 in early April and a right shoulder around $93.63; the neckline is roughly $92.39. The company reported a Q1 2026 net loss of $2.28 per share and revenue of $138 million, down about 28% year‑over‑year, and affirmed full‑year sales guidance of €2.328 billion to €2.678 billion. Options positioning showed a put‑call ratio near 2.23 by volume and 1.15 by open interest during the period. A daily close below $92.39 would point to further weakness toward $86.64 and then supports near $79.31 and $72.36; a daily close above $100.47 would begin to erode the bearish setup and a move above $113.55 would negate it.

The outbreak coincided with increased trading in companies connected to mRNA vaccine platforms and government medical countermeasures. During the period market participants cited company results, program announcements and technical chart levels when adjusting positions in these stocks.